Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Brief Summary: This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy and NKTR-255, and to see how well they work in treating patients with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. These proteins are commonly found on diffuse large B-cell lymphoma and B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. Giving CD19/CD22-CAR T cells and chemotherapy in combination with NKTR-255 may work better in treating patients with diffuse large B-cell lymphoma or B acute lymphoblastic leukemia.


Options:
A: Intervention Type: PROCEDURE; Name: Procedure - Adoptive cell transfer; Assigned to Arm(s): N/A
B: Arm Label: Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255); Type: EXPERIMENTAL; Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Other: Questionnaire Administration, Drug: NKTR-255 | Intervention Type: BIOLOGICAL; Name: Chimeric Antigen Receptor T-Cell Therapy; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255) | Intervention Type: DRUG; Name: NKTR-255; Assigned to Arm(s): Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255)
C: Arm Label: Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT); Type: EXPERIMENTAL; Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation, Drug: Carmustine, Drug: Cytarabine, Drug: Etoposide, Biological: Filgrastim, Drug: Melphalan, Biological: Rituximab, Biological: Umbilical Cord Blood-derived Natural Killer Cells | Intervention Type: PROCEDURE; Name: Autologous Hematopoietic Stem Cell Transplantation; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: DRUG; Name: Carmustine; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT) | Intervention Type: BIOLOGICAL; Name: Umbilical Cord Blood-derived Natural Killer Cells; Assigned to Arm(s): Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FBTA05 | Intervention Type: DRUG; Name: FBTA05; Assigned to Arm(s): 1

Answer: B